Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Citi
Merck
Julphar
Argus Health
Queensland Health
Colorcon
Accenture
Federal Trade Commission

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Azetidine-2-carboxylic acid derivatives
Abstract:New proline derivatives and related compounds which have the general formula ##STR1## are useful as angiotensin converting enzyme inhibitors.
Inventor(s): Ondetti; Miguel Angel (Princeton, NJ), Cushman; David W. (West Windsor, NJ)
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Filing Date:Feb 13, 1976
Application Number:05/657,792
Claims:1. A compound of the formula ##STR14## wherein R is hydroxy, amino or lower alkoxy;

R.sub.1 and R.sub.4 each is hydrogen, lower alkyl or phenyl-lower alkyl;

R.sub.2 is hydrogen or R.sub.5 --CO;

R.sub.3 is hydrogen, hydroxy or lower alkyl;

R.sub.5 is lower alkyl, phenyl or phenyl-lower alkyl;

m is 1;

n is 0, 1 or 2.

and basic salts thereof.

2. A compound as in claim 1 wherein R is hydroxy or lower alkoxy; R.sub.1 is hydrogen or lower alkyl; R.sub.2 is hydrogen or R.sub.5 --CO; R.sub.3 and R.sub.4 each is hydrogen; R.sub.5 is lower alkyl or phenyl; m is 1 and n is 0, 1 or 2.

3. A compound as in claim 1 wherein R.sub.3 and R.sub.4 each is hydrogen.

4. A compound as in claim 1 wherein m is 1 and R.sub.3 is hydrogen.

5. The L-form of a compound of claim 1.

6. A compound as in claim 1 wherein R is hydroxy.

7. A compound as in claim 1 wherein n is 1.

8. A compound as in claim 1 wherein R.sub.2 is hydrogen or lower alkanoyl.

9. A compound as in claim 1 wherein R.sub.2 is hydrogen.

10. A compound as in claim 1 wherein R.sub.2 is acetyl.

11. A compound as in claim 1 wherein R.sub.1 is hydrogen or lower alkyl.

12. A compound as in claim 1 wherein R.sub.1 is hydrogen or methyl.

13. A compound as in claim 1 wherein R is hydroxy and R.sub.1 is hydrogen or methyl.

14. A composition comprising a compound of claim 1 in an amount sufficient to reduce blood pressure by inhibiting the conversion of angiotension I to angiotension II and a pharmaceutically acceptable vehicle therefor.

15. A method for reducing blood pressure by inhibiting the conversion of angiotensin I to angiotensin II which comprises administering a composition comprising a compound of claim 1 in an amount sufficient to reduce blood pressure by inhibiting the conversion of angiotension I to angiotension II and a pharmaceutically acceptable vehicle therefor.

16. A compound as in claim 1 wherein n is 0.

17. A compound as in claim 16 wherein R is hydroxy, R.sub.1 and R.sub.3 each is hydrogen and R.sub.2 is benzoyl.

18. A compound as in claim 16 wherein R is hydroxy and R.sub.1, R.sub.2 and R.sub.3 each is hydrogen.

19. A compound as in claim 7 wherein R is hydroxy and R.sub.1, R.sub.2, R.sub.4 and R.sub.3 each is hydrogen.

20. A compound as in claim 7 wherein R is hydroxy, R.sub.1 is methyl and R.sub.2, R.sub.4 and R.sub.3 each is hydrogen.

21. The compound of claim 18 wherein the azetidine is in the L-form.

22. The compound of claim 19 wherein the azetidine is in the L-form.

23. The compound of claim 20 wherein the azetidine is in the L-form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Mallinckrodt
Federal Trade Commission
Teva
Chinese Patent Office
Covington
Cantor Fitzgerald
Novartis
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot